Alexa B. Kimball

2000–2025 年に発表

138
論文数
22,398
被引用数
82
h 指数
134
i10 指数

被引用数

Alexa B. Kimball の年別被引用数1964 年: 被引用 1 件1984 年: 被引用 1 件1998 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 2 件2003 年: 被引用 7 件2004 年: 被引用 8 件2005 年: 被引用 13 件2006 年: 被引用 23 件2007 年: 被引用 42 件2008 年: 被引用 88 件2009 年: 被引用 117 件2010 年: 被引用 123 件2011 年: 被引用 165 件2012 年: 被引用 170 件2013 年: 被引用 159 件2014 年: 被引用 165 件2015 年: 被引用 165 件2016 年: 被引用 178 件2017 年: 被引用 278 件2018 年: 被引用 286 件2019 年: 被引用 883 件2020 年: 被引用 901 件2021 年: 被引用 857 件2022 年: 被引用 628 件2023 年: 被引用 608 件2024 年: 被引用 1,001 件2025 年: 被引用 482 件2026 年: 被引用 6 件1965〜1983 年は被引用が無いため表示していません1985〜1997 年は被引用が無いため表示していません1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,010 件、この内訳の 25.1%ドイツ: 引用元論文 603 件、この内訳の 7.5%イギリス: 引用元論文 547 件、この内訳の 6.8%カナダ: 引用元論文 482 件、この内訳の 6%イタリア: 引用元論文 479 件、この内訳の 6%中国: 引用元論文 342 件、この内訳の 4.3%フランス: 引用元論文 310 件、この内訳の 3.9%スペイン: 引用元論文 276 件、この内訳の 3.4%デンマーク: 引用元論文 247 件、この内訳の 3.1%オランダ: 引用元論文 228 件、この内訳の 2.8%日本: 引用元論文 213 件、この内訳の 2.6%スイス: 引用元論文 210 件、この内訳の 2.6%
0%25.1%その他 25.9%

分野

  • Medicine47.6%
  • Immunology and Microbiology41.2%
  • Biochemistry, Genetics and Molecular Biology4.3%
  • Neuroscience2%
  • Health Professions2%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • その他2.4%

トピック

  • Psoriasis: Treatment and Pathogenesis16%
  • Dermatology and Skin Diseases9.5%
  • Spondyloarthritis Studies and Treatments7%
  • Hidradenitis Suppurativa and Treatments6.5%
  • Acne and Rosacea Treatments and Effects3.7%
  • Colorectal and Anal Carcinomas2.5%
  • その他54.8%

共著者

全論文

検索で開く
  1. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shoba Ravichandran, Elisa Muscianisi - The Lancet 2023 被引用: 302

  2. Hidradenitis suppurativa

    著者: , , , , , - Nature Reviews Disease Primers 2020 被引用: 560

  3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    著者: , , , , , , , - Journal of the American Academy of Dermatology 2017 被引用: 860

  4. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 777

  5. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    著者: , , , , , , , , , , , , , - The Lancet 2017 被引用: 556

  6. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula - New England Journal of Medicine 2015 被引用: 806

  7. Development and validation of the International Hidradenitis Suppurativa Severity Score System ( IHS 4), a novel dynamic scoring system to assess HS severity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Florentina Delli, Clio Dessinioti, Aikaterini Patsatsi, Anastasia Trigoni, C. Zisimou, Vincenzo Bettoli, Simone Garcovich, Jurr Boer, Barbara Horváth, G. Ingvarsson, L. Puig, Robert E. Hunger, Lennart Emtestam, F. William Danby, Alexa B. Kimball - British Journal of Dermatology 2017 被引用: 454

  8. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    著者: , , , , , , , , - The Lancet 2008 被引用: 1,865

  9. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2024 被引用: 164

  10. Impact of Endometriosis on Life-Course Potential: A Narrative Review

    著者: , , , , , , , , , , , , , , - International Journal of General Medicine 2021 被引用: 209

  11. Aging-Associated Changes in the Adult Human Skin Microbiome and the Host Factors that Affect Skin Microbiome Composition

    著者: , , , , , , , , , , , , , , , - Journal of Investigative Dermatology 2021 被引用: 103

  12. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

    著者: , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2019 被引用: 376

  13. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2021 被引用: 222

  14. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis

    著者: , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2006 被引用: 673

  15. The Impact of Administrative Burden on Academic Physicians: Results of a Hospital-Wide Physician Survey

    著者: , , , , , , - Academic Medicine 2016 被引用: 240

  16. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

    著者: , , - Journal of the European Academy of Dermatology and Venereology 2013 被引用: 351

  17. Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial

    著者: , , , , , , , , , , - Dermatology and Therapy 2023 被引用: 57

  18. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jashin J. Wu, Min Zheng - Journal of the American Academy of Dermatology 2019 被引用: 243

  19. What causes hidradenitis suppurativa ?—15 years after

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , André Nogueira da Costa, Martin M. Okun, Lauren A.V. Orenstein, J.C. Pascual, Ralf Paus, Benjamin Perin, Errol P. Prens, Till A. Röhn, Andrea Szegedi, Jacek C. Szepietowski, Thrasyvoulos Tzellos, Baoxi Wang, Hessel H. van der Zee - Experimental Dermatology 2020 被引用: 187

  20. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

    著者: , , , , , , , , , , - Journal of the American Academy of Dermatology 2023 被引用: 66

  21. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

    著者: , , , , , , , - Journal of the European Academy of Dermatology and Venereology 2015 被引用: 193

  22. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

    著者: , , , , , , , , , , , , , , , , - Journal of the European Academy of Dermatology and Venereology 2018 被引用: 251

  23. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

    著者: , , , , , , , , , , - British Journal of Dermatology 2023 被引用: 99

  24. The Psychosocial Burden of Psoriasis

    著者: , , , , - American Journal of Clinical Dermatology 2005 被引用: 558